Results 131 to 140 of about 34,440,044 (184)

Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review. [PDF]

Gastro Hep Adv
Desai A, Habib H, Wahbeh L, Farraye FA.
europepmc   +1 more source

Receipt of glucagon-like peptide-1 receptor agonists among rural patients with obstructive sleep apnea and excess weight. [PDF]

Ann Am Thorac Soc
Leonhard AG, Josey K, Castaneda JM, Chee M, Duan KI, Nadeem H, Plumley R, Triplette M, Smith NL, Au DH, Feemster LC, Donovan LM.   +11 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes.

JAMA Netw Open
Hamad CD, Wiener J, Golzar A, Kaur H, Henein C, Kittredge AP, Su G, Kaelber DC, Chan L, Yeaman MR, Adams JS, Bernthal NM, Sheppard WL.   +12 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists

Surgical Clinics of North America
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Heather P. Whitley, Jennifer M. Trujillo
core   +12 more sources

Some of the next articles are maybe not open access.

Related searches:

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
Sadiya S, Khan, Chiadi E, Ndumele, Dhruv S, Kazi   +2 more
openaire   +2 more sources